Catalio Capital Management Invests in ProSomnus Sleep Technologies

ProSomnus Sleep Technologies has secured a strategic investment from Catalio Capital Management L.P. to accelerate the global expansion of its technology-enabled sleep health platform.

“Catalio’s investment affirms our mission to address the global public health burden of obstructive sleep apnea with precision, data‑driven medical solutions that create meaningful value loops for patients, clinicians, and payers,” ProSomnus CEO Len Liptak said. “Demand for effective, economical, and patient‑preferred therapies continues to build. This partnership enables ProSomnus to expand access to care while advancing and scientifically validating our next-generation sensor‑enabled medical devices. We appreciate Catalio’s partnership and look forward to accelerating the worldwide adoption of Smart Sleep Medicine.”

Under the agreement, Catalio will commit up to $38 million to advance the development of next-generation remote patient monitoring (RPM) and proprietary sleep diagnostic devices, fund comparative clinical studies, and scale the necessary infrastructure to meet surging demand for patient-preferred OSA therapies.

“This $38 million commitment provides the strategic financial framework to scale our core infrastructure while maintaining a relentless focus on the patient,” ProSomnus Chief Financial Officer Jason Orchard added. “By directing capital into advanced remote monitoring and rigorous clinical validation, we are ensuring our growth is measured not just by market share, but by demonstrable patient outcomes. These investments allow us to lower the cost of care, increase treatment efficacy, and create a sustainable model for both our shareholders and the patients we serve.”

Owing to the investment, Catalio’s Dr. Nicholas von Guionneau has joined the ProSomnus Board as an observer. “Sleep medicine is rapidly shifting toward data-driven, patient-preferred therapies. ProSomnus is leading that transition with connected oral devices that are clinically effective and consistently used by patients,” Dr. von Guionneau commented. “We’re excited to strategically support the global launch of their next-generation product and broader vision for a scalable connected sleep medicine platform.”

ProSomnus has created a technology-enabled, non-CPAP alternative for treating obstructive sleep apnea (OSA). A serious medical disease affecting more than 1 billion people worldwide, OSA is linked to life-threatening comorbidities, including heart failure, stroke, and type 2 diabetes.

By integrating precision-engineered intraoral medical devices with advanced remote patient monitoring (RPM) and data-driven diagnostics, ProSomnus is attempting to redefine the standard of care. Its platform provides continuous, nightly clinical insights that ensure adherence and validated patient outcomes. Non-invasive and patient-preferred, ProSomnus devices have demonstrated exceptional efficacy and safety across a rigorous and growing body of clinical evidence, according to the company. ProSomnus precision devices are U.S. Food and Drug Administration-cleared, patented, and covered by commercial medical insurance, Medicare, and TRICARE, representing more than 200 million covered lives globally.

Catalio Capital Management is a New York-based investment firm focused on the full lifecycle of healthcare investing across private, public, and credit markets. Catalio has exclusive partnerships with serial scientist-entrepreneurs worldwide, each of whom have extensive academic and scientific achievements and who have also started multiple well-established companies based on their research. Catalio maintains offices in New York, London, and Washington, D.C.